{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T13:05:12Z","timestamp":1765199112239,"version":"3.46.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2023R1A2C1003916","RS-2025-02214129"],"award-info":[{"award-number":["2023R1A2C1003916","RS-2025-02214129"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002636","name":"Inje University","doi-asserted-by":"publisher","award":["20230159"],"award-info":[{"award-number":["20230159"]}],"id":[{"id":"10.13039\/501100002636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Genom"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13258-025-01689-w","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:21:10Z","timestamp":1760520070000},"page":"1293-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic regulation of Cereblon in cancer: molecular mechanisms and clinical implications"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8341-330X","authenticated-orcid":false,"given":"Joo Mi","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neures.2010.12.019","volume":"69","author":"M Aizawa","year":"2011","unstructured":"Aizawa M, Abe Y, Ito T, Handa H, Nawa H (2011) mRNA distribution of the thalidomide binding protein cereblon in adult mouse brain. Neurosci Res 69:343\u2013347","journal-title":"Neurosci Res"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","volume":"121","author":"A Broyl","year":"2013","unstructured":"Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM et al (2013) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121:624\u2013627","journal-title":"Blood"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M et al (2014) Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 21:803\u2013809","journal-title":"Nat Struct Mol Biol"},{"key":"1689_CR4","first-page":"287","volume":"2","author":"XB Chang","year":"2011","unstructured":"Chang XB, Stewart AK (2011) What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2:287\u2013294","journal-title":"Int J Biochem Mol Biol"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1878-0261.12157","volume":"12","author":"K Dimopoulos","year":"2018","unstructured":"Dimopoulos K, S\u00f8gaard Helbo A, Fibiger Munch-Petersen H, Sj\u00f6 L, Christensen J, Sommer Kristensen L, Asmar F, Hermansen NEU, O\u2019Connel C, Gimsing P et al (2018) Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol Oncol 12:180\u2013195","journal-title":"Mol Oncol"},{"key":"1689_CR6","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38430","volume":"7","author":"KA Donovan","year":"2018","unstructured":"Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, Ebert BL, Fischer ES (2018) Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7:e38430","journal-title":"Elife"},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.12291","volume":"161","author":"JB Egan","year":"2013","unstructured":"Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi C-X, Schmidt J et al (2013) Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 161:748\u2013751","journal-title":"Br J Haematol"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner R, Heider M, Fern\u00e1ndez-S\u00e1iz V, van Bebber F, Garz A-K, Lemeer S, Rudelius M, Targosz B-S, Jacobs L, Knorn A-M et al (2016) Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 22:735\u2013743","journal-title":"Nat Med"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer ES, B\u00f6hm K, Lydeard JR, Yang H, Stadler MB, Cavadini S, Nagel J, Serluca F, Acker V, Lingaraju GM et al (2014) Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512:49\u201353","journal-title":"Nature"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN et al (2020) Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 38:675\u2013678","journal-title":"Nat Biotechnol"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1067\/mhj.2002.125628","volume":"144","author":"L Gullestad","year":"2002","unstructured":"Gullestad L, Semb AG, Holt E, Sk\u00e5rdal R, Ueland T, Yndestad A, Fr\u00f8land SS, Aukrust P (2002) Effect of thalidomide in patients with chronic heart failure. Am Heart J 144:847\u2013850","journal-title":"Am Heart J"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1161\/CIRCULATIONAHA.105.564971","volume":"112","author":"L Gullestad","year":"2005","unstructured":"Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, F\u00f8lling M, Hodt A, Sk\u00e5rdal R, Kjekshus J et al (2005) Effect of thalidomide on cardiac remodeling in chronic heart failure. Circulation 112:3408\u20133414","journal-title":"Circulation"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.2020010452","volume":"138","author":"L Haertle","year":"2021","unstructured":"Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Fern\u00e1ndez RA, Bittrich M, Ruiz-Heredia Y, Da Vi\u00e1 M et al (2021) Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood 138:1721\u20131726","journal-title":"Blood"},{"key":"1689_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314624","author":"YK Han","year":"2022","unstructured":"Han YK, Park HY, Park S-G, Hwang JJ, Park HR, Yi JM (2022) Promoter methylation of cancer stem cell surface markers as an epigenetic biomarker for prognosis of oral squamous cell carcinoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314624","journal-title":"Int J Mol Sci"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","volume":"81","author":"M Heider","year":"2021","unstructured":"Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, Lawatscheck J, Baek K, Garz A-K, Rudelius M et al (2021) The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell 81:1170-1186.e1110","journal-title":"Mol Cell"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.12338","volume":"161","author":"D Heintel","year":"2013","unstructured":"Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, Pfeifer S, Gisslinger H, Zojer N, J\u00e4ger U et al (2013) High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 161:695\u2013700","journal-title":"Br J Haematol"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","volume":"63","author":"JJ Higgins","year":"2004","unstructured":"Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63:1927\u20131931","journal-title":"Neurology"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3109\/01677060903567849","volume":"24","author":"JJ Higgins","year":"2010","unstructured":"Higgins JJ, Tal AL, Sun X, Hauck SCR, Hao J, Kosofosky BE, Rajadhyaksha AM (2010) Temporal and spatial mouse brain expression of Cereblon, an ionic channel regulator involved in human intelligence. J Neurogenet 24:18\u201326","journal-title":"J Neurogenet"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345\u20131350","journal-title":"Science"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.3892\/ol.2017.6502","volume":"14","author":"Y Jian","year":"2017","unstructured":"Jian Y, Gao W, Geng C, Zhou H, Leng Y, Li Y, Chen W (2017) Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett 14:3243\u20133248","journal-title":"Oncol Lett"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683\u2013692","journal-title":"Cell"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1080\/10428194.2019.1571201","volume":"60","author":"A Kalff","year":"2019","unstructured":"Kalff A, Khong T, Mithraprabhu S, Bergin K, Reynolds J, Bowen KM, Thakurta A, Guzman R, Wang M, Couto S et al (2019) Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Leuk Lymphoma 60:2143\u20132151","journal-title":"Leuk Lymphoma"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","volume":"122","author":"JH Kim","year":"2011","unstructured":"Kim JH, Scialli AR (2011) Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122:1\u20136","journal-title":"Toxicol Sci"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13148-019-0715-0","volume":"11","author":"SY Kim","year":"2019","unstructured":"Kim SY, Han YK, Song JM, Lee CH, Kang K, Yi JM, Park HR (2019) Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC). Clin Epigenetics 11:116","journal-title":"Clin Epigenetics"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X et al (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343:301\u2013305","journal-title":"Science"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK et al (2015) Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523:183\u2013188","journal-title":"Nature"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.omto.2020.06.013","volume":"18","author":"L Li","year":"2020","unstructured":"Li L, Xue W, Shen Z, Liu J, Hu M, Cheng Z, Wang Y, Chen Y, Chang H, Liu Y et al (2020) A cereblon modulator CC-885 induces CRBN- and p97-dependent PLK1 degradation and synergizes with Volasertib to suppress lung cancer. Molecular Therapy - Oncolytics 18:215\u2013225","journal-title":"Molecular Therapy - Oncolytics"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549\u2013557","journal-title":"N Engl J Med"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456\u20131465","journal-title":"N Engl J Med"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai Y-T, Hideshima T, Anderson KC et al (2019) A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia 33:171\u2013180","journal-title":"Leukemia"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326\u20132335","journal-title":"Leukemia"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong K-K, Bradner JE, Kaelin WG (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343:305\u2013309","journal-title":"Science"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, Pagarigan B, Lu C-C, Miller K, Fang W, Wang N-Y, Nguyen D, Houston J et al (2016) A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535:252\u2013257","journal-title":"Nature"},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41594-020-0405-9","volume":"27","author":"ME Matyskiela","year":"2020","unstructured":"Matyskiela ME, Clayton T, Zheng X, Mayne C, Tran E, Carpenter A, Pagarigan B, McDonald J, Rolfe M, Hamann LG et al (2020) Crystal structure of the SALL4\u2013pomalidomide\u2013cereblon\u2013DDB1 complex. Nat Struct Mol Biol 27:319\u2013322","journal-title":"Nat Struct Mol Biol"},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12920-019-0514-7","volume":"12","author":"S-J Park","year":"2019","unstructured":"Park S-J, Yoon B-H, Kim S-K, Kim S-Y (2019) GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics 12:101","journal-title":"BMC Med Genomics"},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/eurheartj\/ehac072","volume":"43","author":"N Park","year":"2022","unstructured":"Park N, Marquez J, Pham TK, Ko TH, Youm JB, Kim M, Choi SH, Moon J, Flores J, Ko KS et al (2022) Cereblon contributes to cardiac dysfunction by degrading Cav1.2\u03b1. Eur Heart J 43:1973\u20131989","journal-title":"Eur Heart J"},{"key":"1689_CR37","doi-asserted-by":"crossref","unstructured":"Polycarpou A, Walker SL, Lockwood DNJ (2017) A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum. Frontiers in Immunology Volume 8 - 2017","DOI":"10.3389\/fimmu.2017.00233"},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/2040620711413165","volume":"2","author":"W Rehman","year":"2011","unstructured":"Rehman W, Arfons LM, Lazarus HM (2011) The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol 2:291\u2013308","journal-title":"Ther Adv Hematol"},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00109-012-0885-0","volume":"90","author":"S Ren","year":"2012","unstructured":"Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu J, Wei M, Lu X, Gao X et al (2012) Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med 90:1121\u20131132","journal-title":"J Mol Med"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","volume":"38","author":"SR Schuster","year":"2014","unstructured":"Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi C-X, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV et al (2014) The clinical significance of cereblon expression in multiple myeloma. Leuk Res 38:23\u201328","journal-title":"Leuk Res"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/cas.14352","volume":"111","author":"T Tachita","year":"2020","unstructured":"Tachita T, Kinoshita S, Ri M, Aoki S, Asano A, Kanamori T, Yoshida T, Totani H, Ito A, Kusumoto S et al (2020) Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma. Cancer Sci 111:1333\u20131343","journal-title":"Cancer Sci"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1038\/s41598-020-61027-w","volume":"10","author":"S Tateno","year":"2020","unstructured":"Tateno S, Iida M, Fujii S, Suwa T, Katayama M, Tokuyama H, Yamamoto J, Ito T, Sakamoto S, Handa H et al (2020) Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci Rep 10:4012","journal-title":"Sci Rep"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","volume":"28","author":"A Thakurta","year":"2014","unstructured":"Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA et al (2014) Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 28:1129\u20131131","journal-title":"Leukemia"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1074\/jbc.RA118.002246","volume":"293","author":"J Yang","year":"2018","unstructured":"Yang J, Huang M, Zhou L, He X, Jiang X, Zhang Y, Xu G (2018) Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun. J Biol Chem 293:10141\u201310157","journal-title":"J Biol Chem"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.10.003","volume":"440\u2013441","author":"J Zheng","year":"2019","unstructured":"Zheng J, Sha Y, Roof L, Foreman O, Lazarchick J, Venkta JK, Kozlowski C, Gasparetto C, Chao N, Ebens A et al (2019) Pan-PIM kinase inhibitors enhance Lenalidomide\u2019s anti-myeloma activity via cereblon-IKZF1\/3 cascade. Cancer Lett 440\u2013441:1\u201310","journal-title":"Cancer Lett"},{"key":"1689_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41419-019-1317-7","volume":"10","author":"L Zhou","year":"2019","unstructured":"Zhou L, Xu G (2019) Cereblon attenuates DNA damage-induced apoptosis by regulating the transcription-independent function of p53. Cell Death Dis 10:69","journal-title":"Cell Death Dis"},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/hmg\/ddx433","volume":"27","author":"L Zhou","year":"2018","unstructured":"Zhou L, Hao Z, Wang G, Xu G (2018) Cereblon suppresses the formation of pathogenic protein aggregates in a p62-dependent manner. Hum Mol Genet 27:667\u2013678","journal-title":"Hum Mol Genet"},{"key":"1689_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.605989","volume":"8","author":"L Zhou","year":"2020","unstructured":"Zhou L, Yu W, Jayabalan DS, Niesvizky R, Jaffrey SR, Huang X, Xu G (2020) Caspase-8 inhibition prevents the cleavage and degradation of E3 ligase substrate receptor cereblon and potentiates its biological function. Front Cell Dev Biol 8:605989","journal-title":"Front Cell Dev Biol"},{"key":"1689_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.121.000818","volume":"379","author":"L Zhou","year":"2021","unstructured":"Zhou L, Huang X, Niesvizky R, Pu Z, Xu G (2021) Caspase-8 regulates the antimyeloma activity of bortezomib and lenalidomide. J Pharmacol Exp Ther 379:303\u2013309","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Genes & Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-025-01689-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13258-025-01689-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13258-025-01689-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T13:02:47Z","timestamp":1765198967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13258-025-01689-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s13258-025-01689-w","relation":{},"ISSN":["1976-9571","2092-9293"],"issn-type":[{"type":"print","value":"1976-9571"},{"type":"electronic","value":"2092-9293"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}